All In Biotech

Drug Trial Radar · NCT07516093

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Oct 2029

Study completion Aug 2033

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.

Conditions

  • B-cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • NX-5948Drug

    Administered orally once daily

  • PirtobrutinibDrug

    Administered orally once daily per prescribing information

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) as assessed by Independent Review Committee (IRC)Time frame: Up to approximately 3.5 years
  2. Objective response rate (ORR) without partial response with lymphocytosis (PR-L) as assessed by IRCTime frame: Up to approximately 2.5 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Central Georgia Cancer Care

    Macon, Georgia · Recruiting

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana · Recruiting

  • Hematology Oncology of Indiana

    Indianapolis, Indiana · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology - West Texas

    Midland, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.